8/27/2015 | 1 Dutch Universities: Research with Focus on Top Sectors. Cooperation with Russia in Field of Life-Science & Health Sibrandes Poppema 400 years of Passion & Performance Since 1614

Scientific output USA3,250,38051,546, PEOPLES REP CHINA1,022,597 6,653, GERMANY 845,44811,340, JAPAN 803,857 8,390, ENGLAND 747,86711,306, FRANCE 603,328 7,556, CANADA 493,736 6,588, ITALY 470,648 5,689, SPAIN 382,658 4,079, AUSTRALIA 338,947 4,098, INDIA 334,660 2,059, SOUTH KOREA 325,403 2,385, NETHERLANDS 276,918 4,376, RUSSIA 275,325 1,371, /27/2015 | 2

3 Publications In Nature or Science University rankings Nature Publishing Index: 85 Scientist Best Places to Work in Academia: 24 New York Times Employability: 81

University-Business cooperation (Netherlands)  Public-Private Partnerships in top-institutes (investigator driven, precompetitive with industry)  Intermediate (industry driven, with investigators)  New: top-sector policy (9 areas, government policy). 8/27/2015 | 4 Horticulture Agri & Food Water Life sciences & Health Chemistry High tech Energy Logistics Creative industry Head offices

Topsector Life Sciences Source: Topsectorplan Life Sciences and Health Healthy Ageing

8/27/2015 | 6 University Medical Center 1797

8/27/2015 | 7 Zernike Science Campus

1. Healthy ageing (HANNN) Biobank & Cohort study Lifelines (165,000 participants) European Research Institute on the Biology of Ageing ERIBA 2. Energy (Energy Valley) Energy Academy Europe EAE Energy Delta Institute EDI Groningen Centre of Energy Law Relevance to Society Multidisciplinary, University, Industry, Governments & Public Participation ENTRANCE: multitesting facility Energy Academy Europe 3. Sustainable Society

Relative contributions of genetics and life style to health and disease LifeLines is a prospective cohort study and Biobank that will follow 165,000 participants in a 3-generation design for at least 30 years. The focus is on multifactorial, age- related disorders. Funding: ~120 Million Euro September 2012: th participant Healthy Ageing: LifeLines

LifeLines cohort dimensions Index persons (25-50 years) partner father mother partner’s father partner’s mother child Aselect: Partner: Children: Total number of participants: Parents alive: child Healthy Ageing: LifeLines

European Research Institute on the Biology of Ageing ERIBA Fundamental questions on the biological causes of stem cell ageing

European Research Institute on the Biology of Ageing Dr. Christian Riedel Team Leader: Laboratory of Molecular Mechanisms in Lifespan Regulation. Dr. Peter Lansdorp Scientific Director Team Leader: Laboratory of Genetic Instability, Ageing and Cancer ERC advanced grant 2011 Dr. Gerald de Haan Scientific Co-Director Team Leader: Laboratory of Ageing Biology and Stem Cells Dr. Michael Chang Team Leader: Laboratory of Telomeres and Genome Integrity Dr. Eugene Berezikov Team Leader: Laboratory of Stem Cell Regulation and Mechanisms of Regeneration ERC starting grant 2012 Dr. Floris Foijer Team Leader: Laboratory of Genomic Instability in Development and Disease Dr. Victor Guryev Team Leader: Laboratory of Genome Structure and Ageing Dr. Ellen Nollen Team Leader: Laboratory of Molecular Neurobiology of Ageing ERC starting grant 2011 Dr. Liesbeth Veenhoff Team Leader: Laboratory of Cellular Biochemistry: Role of nuclear transport in cellular ageing Healthy Ageing International team, prestigious European ERC grants

Clearance of p16 Ink4a -positive senescent cells delays ageing-associated disorders Darren J. Baker, Tobias Wijshake, Tamar Tchkonia, Nathan K. LeBrasseur, Bennett G. Childs, Bart van de Sluis, James L. Kirkland & Jan M. Van Deursen Nature 479, 2 32–236 (10 November 2011) Prevents ageing: kyphosis, cataract etc According to Science one of the top 10 scientific discoveries of 2011 Alliance for Healthy Ageing with Mayo Clinics

Skolkovo Tech Research Investment Strategy 8/27/2015 | 14 Skolkovo Institute of Science and Technology 2012

Skolkovo Tech Strategy – BioMedicine (1) Computational and systems biology – profoundly different approaches to study biological systems, including complex data, in order to support both basic, as well as applied research involving discovery of new drugs and drug targets [high priority] Immunology and infectious disease - in terms of diseases caused by multi-drug resistant bacteria and viral pandemics, the role of microbiome in human health, and organized response to and treatment of disease [high priority, center in negotiation] Gene- and nano-medicine - impacting the understanding of disease, therapeutics and drug delivery [high priority, center in negotiation] Regenerative medicine - stem cell research as well as tissue and organ fabrication [ high priority, center in negotiation with ERIBA, University of Groningen ] 8/27/2015 | 15

8/27/2015 | 16 THANK YOU FOR YOUR ATTENTION Hey Charles, Where are you going? To the University of Groningen, always good to get some additional schooling